Precigen (NASDAQ:PGEN) Shares Gap Up Following Analyst Upgrade

Precigen, Inc. (NASDAQ:PGEN) gapped up before the market opened on Thursday after Citizens Jmp raised their price target on the stock from $8.00 to $9.00. The stock had previously closed at $3.10, but opened at $4.07. Citizens Jmp currently has a market outperform rating on the stock. Precigen shares last traded at $3.9670, with a volume of 10,133,553 shares.

A number of other equities analysts also recently commented on PGEN. HC Wainwright upped their price objective on shares of Precigen from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday. Zacks Research raised shares of Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research note on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $9.50.

Key Stories Impacting Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Management said PAPZIMEOS launch is accelerating with broader U.S. payer coverage and expects Q1 revenue to exceed $18M, signaling strong early commercial demand. Precigen expects Q1 revenue to exceed $18M
• Positive Sentiment: PAPZIMEOS recorded $3.4M of net product revenue in Q4 (first partial commercial quarter); CMS assigned a permanent J‑code (J3404) effective April 1, and the EMA validated a Marketing Authorization Application — all steps that should simplify reimbursement and expand access. Company reports ~$100.4M in cash and investments to fund operations toward cash‑flow breakeven. Precigen Reports Full Year 2025 Financial Results and Business Updates
• Positive Sentiment: Reported EPS of ($0.01) beat consensus (-$0.10), indicating better‑than-expected per‑share performance despite being in a loss position. Precigen Q4 earnings details
• Neutral Sentiment: Management provided additional color on commercial execution and clinical programs during the earnings call and published call transcripts; listeners should review the call for details on sales cadence and launch execution. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Recent short‑interest reports in public feeds appear anomalous (showing zero shares), so short‑interest signals are unreliable at present; treat those data cautiously.
• Negative Sentiment: Q4 revenue of $4.57M missed analysts’ estimates (~$8.29M), a near-term financial disappointment that tempers enthusiasm around the launch ramp. Precigen Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: Technically, the stock has moved below its 200‑day moving average, which can trigger selling from trend‑based investors. Stock Passes Below 200-Day Moving Average

Institutional Investors Weigh In On Precigen

A number of hedge funds and other institutional investors have recently bought and sold shares of PGEN. Lansing Street Advisors purchased a new stake in shares of Precigen during the 3rd quarter worth $1,800,000. Patient Capital Management LLC increased its holdings in shares of Precigen by 62.6% in the 3rd quarter. Patient Capital Management LLC now owns 26,460,848 shares of the biotechnology company’s stock valued at $87,056,000 after purchasing an additional 10,192,107 shares in the last quarter. Diametric Capital LP purchased a new position in shares of Precigen in the 2nd quarter valued at about $476,000. Boxer Capital Management LLC acquired a new stake in shares of Precigen in the third quarter valued at about $2,796,000. Finally, SG Americas Securities LLC lifted its stake in shares of Precigen by 68.4% in the fourth quarter. SG Americas Securities LLC now owns 39,319 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 15,969 shares during the period. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Trading Up 26.0%

The company has a quick ratio of 3.95, a current ratio of 4.04 and a debt-to-equity ratio of 2.22. The business’s fifty day moving average is $4.10 and its 200 day moving average is $3.98. The stock has a market cap of $1.38 billion, a PE ratio of -2.81 and a beta of 1.10.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.